410 related articles for article (PubMed ID: 32903369)
1. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer.
Raimondi A; Sepe P; Zattarin E; Mennitto A; Stellato M; Claps M; Guadalupi V; Verzoni E; de Braud F; Procopio G
Front Oncol; 2020; 10():1644. PubMed ID: 32903369
[TBL] [Abstract][Full Text] [Related]
2. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility of tumor mutational burden in non-small cell lung cancer.
Greillier L; Tomasini P; Barlesi F
Transl Lung Cancer Res; 2018 Dec; 7(6):639-646. PubMed ID: 30505708
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.
Hendriks LE; Rouleau E; Besse B
Transl Lung Cancer Res; 2018 Dec; 7(6):647-660. PubMed ID: 30505709
[TBL] [Abstract][Full Text] [Related]
7. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
9. The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma.
Su J; Zhou L; Zhang Z; Xiao X; Qin Y; Zhou X; Huang T
Front Immunol; 2023; 14():1146738. PubMed ID: 37350955
[TBL] [Abstract][Full Text] [Related]
10. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges.
Yang F; Wang JF; Wang Y; Liu B; Molina JR
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008273
[TBL] [Abstract][Full Text] [Related]
11. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee.
Mino-Kenudson M; Schalper K; Cooper W; Dacic S; Hirsch FR; Jain D; Lopez-Rios F; Tsao MS; Yatabe Y; Beasley MB; Yu H; Sholl LM; Brambilla E; Chou TY; Connolly C; Wistuba I; Kerr KM; Lantuejoul S;
J Thorac Oncol; 2022 Dec; 17(12):1335-1354. PubMed ID: 36184066
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
[No Abstract] [Full Text] [Related]
13. Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
Honrubia-Peris B; Garde-Noguera J; García-Sánchez J; Piera-Molons N; Llombart-Cussac A; Fernández-Murga ML
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503087
[TBL] [Abstract][Full Text] [Related]
14. From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy.
Sesma A; Pardo J; Cruellas M; Gálvez EM; Gascón M; Isla D; Martínez-Lostao L; Ocáriz M; Paño JR; Quílez E; Ramírez A; Torres-Ramón I; Yubero A; Zapata M; Lastra R
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066479
[TBL] [Abstract][Full Text] [Related]
15. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.
Tan Q; Yin S; Zhou D; Chi Y; Man X; Li H
Front Oncol; 2022; 12():779786. PubMed ID: 35646659
[TBL] [Abstract][Full Text] [Related]
16. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
17. Possible Biomarkers for Cancer Immunotherapy.
Otoshi T; Nagano T; Tachihara M; Nishimura Y
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31277279
[TBL] [Abstract][Full Text] [Related]
18. Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models.
Ouzaid I; Rioux-Leclercq N; Khene ZE; Bensalah K; Kammerer-Jacquet SF
Eur Urol Open Sci; 2023 Jan; 47():12-19. PubMed ID: 36573246
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
20. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]